The first of its kind 12m (40ft) mobile medical unit will begin mapping daily routes throughout the Rosebud Sioux Tribe Reservation.

The recent estimate from the International Diabetes Federation (IDF) Diabetes Atlas shows that globally 382 million people have diabetes, a figure that is equal to the combined population of the United States and United Kingdom. People living with diabetes in low- and middle-income countries make up 80% of the total global disease prevalence[1] and many ethnic groups and rural communities do not receive necessary care and access to treatment.

Novo Nordisk’s latest issue of the TBL Quarterly tells the stories of how individuals and coordinated efforts are making a difference in communities and low-income countries to improve availability and access to diabetes care.

Novo Nordisk’s TBL Quarterly is available as a downloadable Adobe PDF. Click here to explore.

Leading change from South Dakota to Guinea

The latest issue of the TBL Quarterly introduces some of the programmes and people who are driving change to improve the prevention and treatment of diabetes.

• 17-year-old Thierno Aliou Diallo helps children who are newly diagnosed with type 1 diabetes in Guinea, Africa, to adapt to a new way of living.
• Connie Brushbreaker drives diabetes prevention and education to improve the health of the Rosebud Sioux Tribe in South Dakota, USA.
• Ben Konate shows how to overcome the ‘no one size fits all’ challenge when breaking down barriers to care in Africa.
• Eyad Al Safadi, Novo Nordisk’s General Manager for Syria, explains how he and his team have kept the supply of insulin open during the conflict.

The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to sustainability@novonordisk.com.

About the TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both stakeholders and shareholders. Published following the company’s quarterly results, Novo Nordisk’s TBL Quarterly offers articles, photos and infographics that demonstrate how responsibility supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.

Explore previous issues of the TBL Quarterly.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. In 2013, Novo Nordisk received the Pharmaceuticals and Biotechnology industry group top ranking on Corporate Knight’s list of Global 100 Most Sustainable Corporations.

[1] International Diabetes Federation. The Diabetes Atlas. Sixth Edition. 2013

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk